3.1 Introduction The process of pre-authorization clinical development is considered complete when the sponsor has collated sufficient evidence of efficacy and safety for the investigated medicinal product. Thereafter, it is…
4.1 Introduction The pharmacovigilance documents associated with risk evaluation and management are often required components of Marketing Authorization Application (MAA) and New Drug Application (NDA) submissions, and thus could have…
6.1 Introduction In addition to the multiplicity of mandated periodic pharmacovigilance documents required for investigational and authorized medicinal products, documents submitted at the time of application for marketing authorization, and…
2.1 Introduction When a company or academic institution is granted permission to test a yet to be authorized medicinal product on human subjects (or an authorized medicinal product in a…
7.1 Introduction For obvious reasons, the main preoccupation of this volume has been to focus on pharmacovigilance medical writing as it is practiced in the EU and US. It would…
In the first instance, the clinical development phase is associated with annual submissions of the Development Safety Update Report (DSUR) in the European Union (EU) and the Investigational New Drug…
Use of Vasopressors and Inotropes in the Pharmacotherapy of Shock Robert Maclaren and Joseph F. Dasta KEY CONCEPTS Continuous hemodynamic monitoring with an arterial catheter or a central…
KEY CONCEPTS Advancing age, inherited and acquired genetic susceptibilities, lifestyle choices, inflammatory bowel disease, type 2 diabetes mellitus, and environmental factors are associated with colorectal cancer risk. Regular…
Chronic Heart Failure Robert B. Parker, Jean M. Nappi, and Larisa H. Cavallari KEY CONCEPTS Heart failure (HF) is a progressive clinical syndrome that can result from any…
Osteoporosis and Other Metabolic Bone Diseases Mary Beth O’Connell and Jill S. Borchert KEY CONCEPTS Osteoporosis is a public health epidemic that affects all ages, genders, races, and…
